AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02277223 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: Eligible patients will be randomized to either intervention of placebo groups. Randomization will be performed separately for patients receiving corticosteroids for induction in-order to ensure similar heterogeneity within groups. Induction: oral prednisone 1mg/kg up to 40 mg once daily for 2 weeks and then tapered down by 5 mg per week or 5-ASA 75 mg/kg/day divided to two doses. Maintenance: 5-ASA 75 mg/kg/day divided to two doses.~Patients receiving corticosteroids for induction, whose PUCAI is >35 points at 2 weeks will be regarded as treatment failure. Patients receiving 5-ASA for induction with induction treatment failure will be re-randomized to receive oral corticosteroids induction with or without curcumin.
Study NCT02277223 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Eligible patients will be randomized to either intervention of placebo groups. Randomization will be performed separately for patients receiving corticosteroids for induction in-order to ensure similar heterogeneity within groups. Induction: oral prednisone 1mg/kg up to 40 mg once daily for 2 weeks and then tapered down by 5 mg per week or 5-ASA 75 mg/kg/day divided to two doses. Maintenance: 5-ASA 75 mg/kg/day divided to two doses.~Patients receiving corticosteroids for induction, whose PUCAI is >35 points at 2 weeks will be regarded as treatment failure. Patients receiving 5-ASA for induction with induction treatment failure will be re-randomized to receive oral corticosteroids induction with or without curcumin.
Study NCT02274012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: Afatinib 40mg/PO daily will be administered in combination to standard of care paclitaxel.
Study NCT02274012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: On the day of the first dose of afatinib, paclitaxel will be administered at a dose of 80 mg/m2 intravenously over 60 minutes on days 1, 8 and 15 of a 28-day cycle.
Study NCT01605240 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen and Ibuprofen
Description: After their fracture is reduced, these patients will receive acetaminophen (15mg/kg) and ibuprofen (10mg/kg) at regular dosing intervals.
Study NCT01605240 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen and Codeine
Description: After their fracture is reduced, these patients will receive acetaminophen (15mg/kg) and codeine (1mg/kg) at regular dosing intervals.
Study NCT03298958 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rapamycin
Description: Subject will be randomized to one of the 2 arms
Study NCT03298958 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Subject will be randomized to one of the 2 arms
Study NCT02541357 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: relaxation program
Description: relaxation and mindfulness techniques such as body scan, breathing meditation or imagination exercises~1 week program, one introductory session and daily home practice
Study NCT02541357 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: surgery education
Description: intensified education unit to reduce anxiety and stress, by using pictures and videos of rooms, and procedures of the planned surgery~1 single unit in the week before the surgery
Study NCT01288937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milnacipran
Description: Patients will be randomly assigned to receive milnacipran 100 mg/day (including a 1 week dose titration period):~Day 1: 12.5 mg once Day 2, 3: 25 mg/day (12.5 mg twice daily) Day 4, 7: 50 mg/day (25 mg twice daily) After Day 7: 100 mg/day (50 mg twice daily)
Study NCT01288937 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will be randomly assigned to placebo for 9 weeks (including a 1 week dose titration period), matching the schedule of the study drug.
Study NCT02854332 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS session
Description: Direct current transcranial magnetic stimulation
Study NCT02854332 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS session
Description: Repetitive transcranial magnetic stimulation.
Study NCT02909335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Tacrolimus is administered at an initial dose of 0.040 mg / kg twice a day on Day 5.~The doses are then adjusted to maintain trough levels :~* between 6 and 10 ng / ml during the first 2 months,~* between 5 and 8 ng / ml from the start of the end M3 and M6,~* and between 4 and 6 ng / ml between the beginning and the end of M7 M12.
Study NCT00647985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fexofenadine Tablets 180 mg
Description: 180mg, single dose fed
Study NCT00647985 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allegra® Tablets 180 mg
Description: 180mg, single dose fed
Study NCT03389321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riociguat (Adempas)
Description: Riociguat film-coated tablets for oral administration at a strength of 1 mg
Study NCT03389321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macitentan (Opsumit)
Description: Macitentan film-coated tablets for oral administration at a strength of 10 mg
Study NCT02909335 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus
Description: Everolimus is administered at an initial dose of 1.5 mg twice a day on Day 5.~The doses are then adjusted to maintain trough levels:~* between 6 and 10 ng / ml during the first 2 months,~* between 5-8 ng / ml from the start of the end M3 and M6,~* and between 4 and 6 ng / ml between the beginning and the end of M7 M12.
Study NCT02909335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: mycophenolate mofetil is administered similarly in the two groups at the dose of 1.5 g for the first two months and then 1 g twice a day. The doses may be adjusted according to the tolerance of the product.
Study NCT02909335 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate mofetil
Description: mycophenolate mofetil is administered similarly in the two groups at the dose of 1.5 g for the first two months and then 1 g twice a day. The doses may be adjusted according to the tolerance of the product.
Study NCT02909335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone, Prednisone or Methylprednisolone
Description: Corticosteroid is similarly administered in both groups between baseline and the end of M6 and adjusted in case of acute rejection
Study NCT02909335 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone, Prednisone or Methylprednisolone
Description: Corticosteroid is similarly administered in both groups between baseline and the end of M6 and adjusted in case of acute rejection
Study NCT01579786 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acetaminophen and acupuncture
Description: All patients will receive acetaminophen (maximum 3g/day) for all seven days after surgery and will receive acupuncture treatment at first day after performing surgery and thirty minutes before operation
Study NCT04299646 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Steretactic radiotherapy
Description: Steretactic radiotherapy
Study NCT03342638 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IVIg
Description: Sterile, purified immunoglobulin G (IgG) products manufactured from pooled human plasma and typically contain more than 95% unmodified IgG, which has intact Fc-dependent effector functions and only trace amounts of immunoglobulin A (IgA) or immunoglobulin M (IgM).
Study NCT03342638 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Stem Cells
Description: Infusion of participant's own stem cells
Study NCT04075123 — intervention group
Intervention type: OTHER
Intervention: CPAP
Description: The two NRS strategies being compared will be initiated at the time of first extubation (NRS support practices prior to initial intubation will be as per local unit guidelines and practices) and all subsequent extubations (if applicable) until 32 weeks PMA. For instance, a unit adopting post-extubation NCPAP strategy will initiate this mode following the initial and all subsequent extubations until 32 weeks PMA whereas centres adopting post-extubation NIPPV will initiate NIPPV following initial and all subsequent extubations until 32 weeks PMA.
Study NCT04424381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 20 MG Oral Tablet [Xarelto]
Description: The subjects randomly received single oral administration of Rivaroxaban 20 MG Oral Tablet \[Xarelto\].
Study NCT04424381 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban 20 MG Oral Tablet
Description: The subjects randomly received single oral administration of Rivaroxaban 20 MG Oral Tablet.
Study NCT01924650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PH-797804
Description: Tablet, 6 mg, single dose
Study NCT00620841 — intervention group
Intervention type: OTHER
Intervention: genotyping
Description: Restriction fragment lenght polymorphisms
Study NCT03512665 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Full dose supplement
Description: A 7ml vial composed of a mixture of pine, macadamia and pomegranate oils.
Study NCT03512665 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low dose Supplement
Description: A 7 mL vial composed of a mixture containing 50% study supplement (Pine, macadamia and pomegranate oils) and 50% sunflower oil.
Study NCT03512665 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control Oil
Description: A 7ml vial composed of sunflower oil with appearance and organoleptic properties similar to those of the supplement provided in the intervention groups.
Study NCT04050826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine 2.5% and Prilocaine 2.5% cream, USP (Actavis Pharma incorporated, USA)
Description: Topical application
Study NCT04050826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine 2.5% and Prilocaine 2.5% cream (E. Fougera & Co. a division of Fougera Pharmaceuticals Inc., USA)
Description: Topical application
Study NCT04050826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oraqix Parodontal-Gel (Dentsply Detrey GmbH, Germany)
Description: Topical application
Study NCT04050826 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dermal open flow microperfusion
Description: Dermal open flow microperfusion will be used to collect interstitial fluid in order to assess lidocaine/prilocaine concentration in the dermis.~16 dOFM probes will be implanted per participant (8 test-sites; 2 dOFM probes per test-site).~From each dOFM probe 13 samples will be taken (1 pre-dose, 12 post-dose).
Study NCT04050826 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: 1 sample will be taken pre-dose and 12 samples post-dose.
Study NCT00003857 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tamoxifen citrate
Study NCT00003857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamoxifen citrate
Study NCT00003857 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: adjuvant therapy
Study NCT00003857 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy
Study NCT00003857 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT03044379 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapivirine gel (0.05%)
Description: MTN-026/IPM 038 will use the HTI pre-filled applicator, the same applicator that has been utilized in other rectal studies.
Study NCT03044379 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Universal HEC placebo gel
Study NCT01298128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NuvaRing
Description: NuvaRIng 21 days for IVF pre-treatment.
Study NCT01298128 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: marvelon
Description: marvelon 21 daily
Study NCT01090453 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK2202083A vaccine
Description: 3 doses given at 2, 4 and 12 months of age
Study NCT01090453 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevenar 13®
Description: 3 co-administered doses
Study NCT01090453 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevenar 13®
Description: 3 co-administered doses
Study NCT01090453 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix hexa™
Description: 3 doses given at 2, 4 and 12 months of age
Study NCT01090453 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Menjugate®
Description: 3 co-administered doses
Study NCT01090453 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotarix™
Description: Oral, two doses
Study NCT01090453 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rotarix™
Description: Oral, two doses
Study NCT01733654 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: RO4995819
Description: The investigation of RO4995819 as adjunctive therapy in MDD patients is supported by preclinical and clinical evidence implicating dysfunction of glutamatergic pathways in the pathophysiology of depression and cognitive disorders, and accumulated evidence of the antidepressant and procognitive effects of mGlu2/3 antagonism.
Study NCT01733654 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RO4995819
Description: The investigation of RO4995819 as adjunctive therapy in MDD patients is supported by preclinical and clinical evidence implicating dysfunction of glutamatergic pathways in the pathophysiology of depression and cognitive disorders, and accumulated evidence of the antidepressant and procognitive effects of mGlu2/3 antagonism.
Study NCT00522275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lacosamide
Description: 50mg or 100 mg tablets, up to 800 mg/day given twice daily (BID) throughout the trial
Study NCT00389558 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: disinfection efficacy using Biseptine
Description: Detersion and antiseptic application when changing catheter dressing
Study NCT00389558 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: disinfection efficacy using Amukin
Description: Detersion and antiseptic application when changing catheter dressing
Study NCT04594161 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Nephrostomy
Description: A Percutaneous Nephrostomy will be placed in patients with obstructive urolithiasis
Study NCT04594161 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Double J catheter
Description: A Double J catheter will be placed in patients with obstructive urolithiasis
Study NCT01507168 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: iv Days 1 and 8, and every 2 weeks thereafter
Study NCT01507168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC33
Description: 1600 mg iv Day 1 and 8, and every 2 weeks thereafter
Study NCT00466518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of sitagliptin
Description: Sitagliptin 100 mg daily for 3 months
Study NCT01192438 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser-based thermotherapy
Description: MRI-guided transperineal placement of a laser probe into the prostate
Study NCT05110092 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: leg resistance combined with breathing exercise training
Description: The exercise group was provided breathing and leg resistance exercise manuals. The exercise involved 5 minutes of abdominal breathing in a relaxed sitting position, followed by 10 minutes of leg resistance training.
Study NCT00754845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole
Description: Given orally
Study NCT00754845 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally
Study NCT01049126 — intervention group
Intervention type: OTHER
Intervention: ChemoFx
Description: Chemoresponse Marker Assay
Study NCT02568241 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interferon Alfa-2b
Description: High-risk acute leukemia patients receive prophylactic DLI at day 30-60 after hematopoietic stem cell transplantation,they received interferon α-2b (subcutaneously at dosages of 3 million units 2-3 times per week) . Interferon treatment continues for 6 months in the absence of disease progression or unacceptable toxicity.
Study NCT03030300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Novolin 30R;Pioglitazone;Metformin
Description: * Insulin (Novolin 30R) was titrated according to the level of blood glucose until reached euglycemia (FPG≤6.1mmol/L and/or P2hBG≤8.0mmol/L and/or HbA1c ≤6.5%). After glucose was well controlled within these targets for 4 weeks, insulin dosage was gradually decreased until discontinued;~* Pioglitazone hydrochloride was discontinued if the glucose was well controlled at the 6th week after the cessation of insulin;~* Metformin was the last drug that to be discontinued if the glucose was still well controlled at the 4th week after the cessation of pioglitazone.
Study NCT01181050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0142-0002
Description: A single dose of 4 mg NNC 0142-0000-0002/kg bodyweight. Administered subcutaneously (s.c., under the skin).
Study NCT01181050 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: A single dose of 4 mg NNC 0142-0000-0002 placebo/kg bodyweight. Administered subcutaneously (s.c., under the skin).
Study NCT03510208 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Near-Infrared Fluorescence Imaging
Description: Undergo NIR imaging
Study NCT03510208 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Given IV
Study NCT03510208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab-IRDye800
Description: Given IV
Study NCT03510208 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: POINPOINT-IR9000
Description: Intraoperative camera capable of exciting and detecting near infrared (NIR) dyes. Imaging will be performed on subjects during surgery and/or on ex-vivo resected tissues in the surgery suite (back table).
Study NCT02457221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus capsules
Description: oral
Study NCT02457221 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide injections
Description: intravenous injection
Study NCT02457221 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: oral
Study NCT04299646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pursuit of ongoing systemic treatment
Description: Pursuit of ongoing systemic treatment
Study NCT04299646 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pursuit of ongoing systemic treatment
Description: Pursuit of ongoing systemic treatment
Study NCT03291431 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent theta burst transcranial magnetic stimulation
Description: 20 iTBS sessions (active or sham) administered over the course of 2 weeks
Study NCT03291431 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Intermittent theta burst transcranial magnetic stimulation
Description: 20 iTBS sessions (active or sham) administered over the course of 2 weeks
Study NCT02949440 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: the caudal-to-cranial approach
Description: Cutting the peritoneum along the line between the right mesocolon and retroperitoneum, enter the Toldt's space to dissect the posterior of Superior mesenteric vein and Superior mesenteric artery and their branches, and then finished the D3 dissection from caudal to cranial on both sides of the mesentery along the Superior mesenteric vein. In the end, cut the lateral ligament to mobilize the posterior space of ascending colon. This approach is called the caudal-to-cranial approach.
Study NCT02949440 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: the medial-to-lateral approach
Description: First, the pedicle of ileocolic vessels is identified and the mesocolon is dissected between the pedicle and the periphery of the Superior mesenteric vein to expose the second portion of the duodenum. The ileocolic vessels are then cut at their roots. The ascending mesocolon is separated from the retroperitoneal tissues, duodenum, and pancreatic head up to the hepatocolic ligament cranially. The important detail in this procedure is the wide separation between the pancreatic head and the transverse mesocolon.This approach is the medial-to-lateral(MtL) approach
Study NCT02457221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: oral
Study NCT02300662 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cycle Ergometer
Description: Passive movement of the cycle ergometer will execute alternate flexions and extensions of the patients' knee and hips bilaterally for 20 minutes consecutively.
Study NCT02300662 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Conventional physiotherapy
Description: Manual bronchial hygiene exercises: vibrocompression, manoeuvres with a manual resuscitator (bag squeezing) and aspiration of secretions where necessary.